Прекращено
Фаза I
Россия
VB6-845 · Sesen Bio, Inc.
A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin